ACSL5 and neoplasm: Therefore, to further examine the function of the fusion protein, we established a patient-derived tumor cell line that carried 2.5 copies of the FGFR2 amplification and the concomitant FGFR2-ACSL5 fusion (PDC#1) and established PDC#2 from a different FGFR2-amplified without fusion patient with GC who was chemotherapy naïve.